| 1.415 -0.015 (-1.05%) | 06-18 10:36 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.25 | 1-year : | 2.67 |
| Resists | First : | 1.92 | Second : | 2.28 |
| Pivot price | 1.55 |
|||
| Supports | First : | 1.34 | Second : | 1.11 |
| MAs | MA(5) : | 1.43 |
MA(20) : | 1.61 |
| MA(100) : | 5.02 |
MA(250) : | 79.56 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 15.3 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 309.89 | Low : | 1.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELAB ] has closed above bottom band by 15.8%. Bollinger Bands are 91.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 111 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.49 - 1.5 | 1.5 - 1.51 |
| Low: | 1.38 - 1.4 | 1.4 - 1.41 |
| Close: | 1.41 - 1.43 | 1.43 - 1.44 |
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Thu, 18 Jun 2026
NorthStrive seeks patents for muscle loss tied to GLP-1 weight-loss drugs - Stock Titan
Wed, 17 Jun 2026
PMGC Holdings Inc (ELAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tue, 16 Jun 2026
Why ELAB Stock Is Crashing Over 50% Overnight After 8x Surge This Week - Stocktwits
Mon, 08 Jun 2026
Shareholders at PMGC Holdings (NASDAQ: ELAB) back staggered board and 2026 auditor - Stock Titan
Fri, 05 Jun 2026
PMGC Holdings (NASDAQ: ELAB) secures FSU patent license and funds $490K research - Stock Titan
Wed, 03 Jun 2026
[Form 4] PMGC Holdings Inc. Insider Trading Activity - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 600 (K) |
| Shares Short P.Month | 236 (K) |
| EPS | -150.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.51 |
| Profit Margin | 0 % |
| Operating Margin | -484.7 % |
| Return on Assets (ttm) | -33.3 % |
| Return on Equity (ttm) | -108 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.18 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.2 |
| Price to Sales | 4.86 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|